Search research articles
Contact Us
Filters
Showing results (511-520 of 591) with videos related to
Page
of 60
Sort By:
The Journal of Urology
|
April 19, 2021
Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, et al.
The Journal of Urology
|
July 9, 2026
Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum
Neal D Shore, Martin Gleave, Ugo De Giorgi, et al.
JACC. Cardiooncology
|
November 16, 2023
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review
Adam J Nelson, Renato D Lopes, Hwanhee Hong, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Andre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
The Journal of Urology
|
July 9, 2026
Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
The Journal of Urology
|
December 5, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
The Journal of Urology
|
December 9, 2025
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
Neal D Shore, Martin Gleave, Ugo De Giorgi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2024
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study
Neal D Shore, Karim Fizazi, Teuvo L J Tammela, et al.
Cancer Medicine
|
December 26, 2025
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
Matthias Saar, Karim Fizazi, Neal D Shore, et al.
Page
of 60
Search research articles
Search
Showing results (511-520 of 591) with videos related to
Sort By:
Page
of 60
The Journal of Urology
|
April 19, 2021
Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, et al.
The Journal of Urology
|
July 9, 2026
Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum
Neal D Shore, Martin Gleave, Ugo De Giorgi, et al.
JACC. Cardiooncology
|
November 16, 2023
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review
Adam J Nelson, Renato D Lopes, Hwanhee Hong, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Nobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology
|
April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Andre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
The Journal of Urology
|
July 9, 2026
Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
The Journal of Urology
|
December 5, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
The Journal of Urology
|
December 9, 2025
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
Neal D Shore, Martin Gleave, Ugo De Giorgi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2024
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study
Neal D Shore, Karim Fizazi, Teuvo L J Tammela, et al.
Cancer Medicine
|
December 26, 2025
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
Matthias Saar, Karim Fizazi, Neal D Shore, et al.
Page
of 60